Foghorn Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Foghorn Therapeutics's past years’ income statements indicate that its last revenue has increased compared to the previous period by 78% to $34,155,000. The net income raised on -$98,426,000 and profit margin reached -288%. Total operating expenses were $142,061,000.
Profit Margin
| 2018 | 0 | -26.33M | |
|---|---|---|---|
| 2019 | 0 | -51.66M | |
| 2020 | 430K | -69.77M | -16227.67% |
| 2021 | 1.31M | -103.22M | -7826.08% |
| 2022 | 19.22M | -108.87M | -566.23% |
| 2023 | 34.15M | -98.42M | -288.17% |
FHTX Income Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Revenue | ||||||
Revenue | 34.15M | 19.22M | 1.31M | 430K | 0 | 0 |
Cost of revenue | 109.68M | 19.22K | 7.51M | 57.71M | 1.79M | 0 |
Gross profit | -75.53M | 19.20M | -6.19M | -57.28M | -1.79M | 0 |
Operating exp. | ||||||
Research and development | 109.68M | 105.61M | 80.32M | 57.71M | 44.36M | 21.22M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 142.06M | 136.36M | 102.05M | 68.96M | 51.08M | 26.04M |
Operating income | -107.90M | -117.13M | -100.73M | -68.53M | -51.08M | -26.04M |
Other income (expenses), net | 13.70M | 8.25M | -586K | -269K | -44K | -30K |
Income before tax | -94.2M | -108.88M | -101.32M | -68.8M | -51.12M | -26.33M |
Income tax expense | 4.22M | -8.25K | 1.90M | 979K | 540K | 83K |
Net income | -98.42M | -108.87M | -103.22M | -69.77M | -51.66M | -26.33M |
Earnings per share | ||||||
Basic EPS | -2.34 | -2.62 | -2.78 | -1.9 | -1.4 | -1.34 |
Diluted EPS | -2.34 | -2.62 | -2.78 | -1.9 | -1.4 | -1.34 |
| Data source | Data source | Data source | Data source |